IPP Bureau
Granules India receives ANDA approval for Bupropion Hydrochloride ER Tablets
By IPP Bureau - October 19, 2024
Granules now has a total of 67 ANDA approvals from the USFDA
Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study
By IPP Bureau - October 19, 2024
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Long-term efficacy and safety profile of Eylea 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
By IPP Bureau - October 19, 2024
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Gland Pharma appoints Shyamakant Giri as CEO
By IPP Bureau - October 19, 2024
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
AstraZeneca advances science of infectious disease protection at IDWeek 2024
By IPP Bureau - October 18, 2024
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
FDA approves VYALEV for adults living with advanced parkinson's disease
By IPP Bureau - October 18, 2024
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
MedGenome completes 10 years in genomics in India
By IPP Bureau - October 18, 2024
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Lupin launches first generic of Pred Forte in US
By IPP Bureau - October 16, 2024
Prednisolone Acetate Ophthalmic Suspension is the first generic version of Pred Forte
Lupin launches Aptivate Achi Bhookh Fest in Mumbai and Suburbs
By IPP Bureau - October 16, 2024
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
By IPP Bureau - October 16, 2024
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Tim Buckley elected to Pfizer’s Board of Directors
By IPP Bureau - October 16, 2024
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Strides Pharma's CDMO arm OneSource raises Rs. 801 crore in pre-listing round
By IPP Bureau - October 16, 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Wockhardt files fast-acting Insulin Aspart injection with DCGI
By IPP Bureau - October 16, 2024
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
Akums Drugs enters into license and distribution agreement with Triple Hair, Canada
By IPP Bureau - October 16, 2024
Akums Drugs will undertake this development and commercialization in India
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
By IPP Bureau - October 16, 2024
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
